202 related articles for article (PubMed ID: 9358509)
1. Changes in repolarization dynamicity and the assessment of the arrhythmic risk.
Maison-Blanche P; Coumel P
Pacing Clin Electrophysiol; 1997 Oct; 20(10 Pt 2):2614-24. PubMed ID: 9358509
[TBL] [Abstract][Full Text] [Related]
2. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
3. [Assessment of QT interval duration in patients with wide QRS].
Guinand A; Namdar M; Burri H; Shah D
Rev Med Suisse; 2016 May; 12(520):1049-53. PubMed ID: 27424344
[TBL] [Abstract][Full Text] [Related]
4. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
Jacobson I; Carlsson L; Duker G
J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive cardiac activation imaging of ventricular arrhythmias during drug-induced QT prolongation in the rabbit heart.
Han C; Pogwizd SM; Killingsworth CR; Zhou Z; He B
Heart Rhythm; 2013 Oct; 10(10):1509-15. PubMed ID: 23773986
[TBL] [Abstract][Full Text] [Related]
6. Analyses of dynamic beat-to-beat QT-TQ interval (ECG restitution) changes in humans under normal sinus rhythm and prior to an event of torsades de pointes during QT prolongation caused by sotalol.
Fossa AA; Wisialowski T; Crimin K; Wolfgang E; Couderc JP; Hinterseer M; Kaab S; Zareba W; Badilini F; Sarapa N
Ann Noninvasive Electrocardiol; 2007 Oct; 12(4):338-48. PubMed ID: 17970959
[TBL] [Abstract][Full Text] [Related]
7. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
Eckardt L; Breithardt G; Haverkamp W
J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
[TBL] [Abstract][Full Text] [Related]
8. Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization: does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes?
Medina-Ravell VA; Lankipalli RS; Yan GX; Antzelevitch C; Medina-Malpica NA; Medina-Malpica OA; Droogan C; Kowey PR
Circulation; 2003 Feb; 107(5):740-6. PubMed ID: 12578878
[TBL] [Abstract][Full Text] [Related]
9. Female gender does not influence the magnitude of ibutilide-induced repolarization delay and incidence of torsades de pointes in an in vivo rabbit model of the acquired long QT syndrome.
Johansson M; Carlsson L
J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):247-54. PubMed ID: 11584331
[TBL] [Abstract][Full Text] [Related]
10. Cellular and ionic basis for T-wave alternans under long-QT conditions.
Shimizu W; Antzelevitch C
Circulation; 1999 Mar; 99(11):1499-507. PubMed ID: 10086976
[TBL] [Abstract][Full Text] [Related]
11. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes.
Antzelevitch C
Heart Rhythm; 2005 Nov; 2(2 Suppl):S9-15. PubMed ID: 16253930
[TBL] [Abstract][Full Text] [Related]
12. Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine.
Sicouri S; Timothy KW; Zygmunt AC; Glass A; Goodrow RJ; Belardinelli L; Antzelevitch C
Heart Rhythm; 2007 May; 4(5):638-47. PubMed ID: 17467634
[TBL] [Abstract][Full Text] [Related]
13. Torsades de pointes and proarrhythmia.
Ben-David J; Zipes DP
Lancet; 1993 Jun; 341(8860):1578-82. PubMed ID: 8099651
[No Abstract] [Full Text] [Related]
14. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
Calderone V; Cavero I
Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
[TBL] [Abstract][Full Text] [Related]
15. Ventricular repolarization dynamicity provides independent prognostic information toward major arrhythmic events in patients with idiopathic dilated cardiomyopathy.
Iacoviello M; Forleo C; Guida P; Romito R; Sorgente A; Sorrentino S; Catucci S; Mastropasqua F; Pitzalis M
J Am Coll Cardiol; 2007 Jul; 50(3):225-31. PubMed ID: 17631214
[TBL] [Abstract][Full Text] [Related]
16. Measuring the risk of torsades de pointes: electrocardiographic evaluation of PNU-142093 in conscious cynomolgus non-human primates using restraint and non-restraint procedures.
Bass AS; Hanson LA; Jackson TA
J Pharmacol Toxicol Methods; 2009; 60(1):51-7. PubMed ID: 19447184
[TBL] [Abstract][Full Text] [Related]
17. Assessment of efficacy of proarrhythmia biomarkers in isolated rabbit hearts with attenuated repolarization reserve.
Orosz S; Sarusi A; Csík N; Papp JG; Varró A; Farkas S; Forster T; Farkas AS; Farkas A
J Cardiovasc Pharmacol; 2014 Sep; 64(3):266-76. PubMed ID: 24887684
[TBL] [Abstract][Full Text] [Related]
18. QT interval measurement in ventricular pacing: Implications for assessment of drug effects and pro-arrhythmia risk.
Schurr JW; Grewal PK; Fan R; Rashba E
J Electrocardiol; 2022; 70():13-18. PubMed ID: 34826635
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
Ahmad K; Dorian P
Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
[TBL] [Abstract][Full Text] [Related]
20. Early afterdepolarizationlike activity in patients with class IA induced long QT syndrome and torsades de pointes.
Kurita T; Ohe T; Shimizu W; Suyama K; Aihara N; Takaki H; Kamakura S; Shimomura K
Pacing Clin Electrophysiol; 1997 Mar; 20(3 Pt 1):695-705. PubMed ID: 9080496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
